Markers of hypercoagulability and risk of death and rehospitalization in heart failure patients: a pilot study on the effects of Fondaparinux

Registry ID
EUCTR2008-001779-31
Source registry
EUCTR
Status
Ongoing
Phase
PHASE3
Sponsor
AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI
Start date
2008-05-09
Last update
2026-08-16

Conditions

Summary

To evaluate the effects of fondaparinux on biochemical parameters and clinical events according to different duration of treatment in heart failure patients (III-IV NYHA). Primary end-point: circulating D-dimer plasma levels 2 months after enrolment

Locations

View on source registry